🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share our latest study! 🧬 We've identified 61 potential exon-skipping strategies for treating dysferlinopathies, theoretically applicable to 90% of reported pathogenic variants. #ExonSkipping #LGMD #MuscularDystrophy mdpi.com/3151468 Cells MDPI UAlberta Med & Dent

🚨New Review Alert! Our latest article explores how machine learning is transforming antisense oligonucleotide therapy design. We discuss AI-driven tools like eSkip-Finder & ASOptimizer and future directions for precision medicine. mdpi.com/3164746 #mdpigenes Genes MDPI

🎉Congratulations to Dr. Hide Moriyama from my lab for being awarded the 2024 Women & Children's Health Research Institute Postdoctoral Fellowship! His research on advancing next-generation therapeutics has been recognized and supported by the Stollery Children's Hospital Foundation.💪 docs.google.com/document/d/1kt…

Our #MostViewed paper in February: "Integrating Machine Learning-Based Approaches into the Design of ASO Therapies" by Jamie Leckie and Prof. Prof. Toshi Yokota PhD FCAHS @MD_Canada Res Chair You can read it at: mdpi.com/2073-4425/16/2…

🚀 Exciting news! Our team has been awarded a $1.3M CIHR grant to study Spinal-Bulbar Muscular Atrophy (SBMA) in Indigenous communities of the Prairie Provinces. Honored to collaborate with an incredible team of researchers & community leaders! neuromuscularnetwork.ca/news/cihr-fund…

in Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy 👉 DOI:10.1371/journal.pone.0120058 Prof. Toshi Yokota PhD FCAHS @MD_Canada Res Chair #Exonskipping #Duchennemusculardystrophy #Antisenseoligonucleotides #Computationalmodeling

Prof. Toshi Yokota PhD FCAHS @MD_Canada Res Chair, WCHRI member, and a team have developed a molecule that bypasses genetic mutations to restore a crucial muscle-repairing protein. This could be life-changing for those with muscular dystrophy. Read more about the Stollery Kids-funded research:

🚀 Exciting progress in gene therapy! Our team at UAlberta Med & Dent has developed a molecule that restores the muscle-repairing protein, offering hope for individuals with #dysferlinopathy. Grateful to our collaborators, patents, and supporters! ualberta.ca/en/folio/2025/… Women & Children's Health Research Institute

📢 Our latest article is now live in Expert Opinion on Drug Safety! 🧬 “Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?” 🔓 I’m excited to share 50 free online copies of the article — available for a limited time! 👉 tandfonline.com/doi/full/10.10…

🚨New Publication! Proud to share our latest review on Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies #DMD. Coauthored with PhD student Umme Sabrina Haque. 🔬🧬 Read it here Dove Medical Press dovepress.com/gene-editing-f…

Excited to share our latest study in Nucleic Acids Research! AOC 1044 successfully induces exon 44 skipping and restores dystrophin in preclinical DMD models—including heart tissue. Proud to collaborate with @AvidityBio! academic.oup.com/nar/article/53… UAlberta Med & Dent

Proud to have hosted Fulbright Scholar Omar Sheikh in the Yokota Lab! As a scientist living with Becker MD, his work on genetic therapies and advocacy for inclusion in science made a lasting impact. Read about his journey. #Fulbright #MuscularDystrophy miusa.org/resource/perso…

Excited to share our latest Muscular Dystrophy Canada –funded project at UAlberta Med & Dent ! We’re developing lipid nanoparticle–based antisense therapy for #FriedreichAtaxia and #SBMA, with a strong focus on Indigenous health equity. #RareDisease #IndigenousHealth #FA muscle.ca/researchers/tr…

🚨 We’re hiring! The Yokota Lab UAlberta Med & Dent is looking for a Postdoctoral Fellow to join our team developing cutting-edge genetic therapies for muscular dystrophy & rare diseases. 🌍 Edmonton, AB 🧪 3-year term (annual renewal) Apply by July 31 👉 jrecin.jst.go.jp/seek/SeekJorDe…

🚨 New publication in Nature Communications! DG9–PMO improves nuclear delivery and exon skipping, restoring muscle & heart function in DMD models. A major step toward cardioprotective therapies. doi.org/10.1038/s41467… Grateful to Muscular Dystrophy Canada CIHR Women & Children's Health Research Institute UAlberta Med & Dent

U of A professor of medical genetics Toshifumi Yokota and the Yokota Lab are making advancements in gene therapy and muscular dystrophy research. buff.ly/xS4wpJg

🚨 Just featured in The Gateway ! Our lab's work on exon skipping & antisense therapy is helping pave the way for genetic treatments that target DMD and beyond. thegatewayonline.ca/2025/05/u-of-a… via The Gateway UAlberta Med & Dent University of Alberta

🎉 Proud to see our postdoc Dr. Hidenori Moriyama featured by Women & Children's Health Research Institute ! His work on improving ASO delivery for muscular dystrophy is bringing new hope to families. Thank you Stollery Kids for supporting this research. wchri.org/our-impact/pos… #RareDisease #WCHRI UAlberta Med & Dent

Excited to share our latest preprint: 🧬 “Brogidirsen and Exon 44 Skipping for DMD: Advances and Challenges in RNA-Based Therapy” preprints.org/manuscript/202… Proud of Annie Tang’s excellent work leading this review. #DMD #RNAtherapy #exonskipping #ASO Preprints.org UAlberta Med & Dent

Congrats to Dr. Hide Moriyama, our talented postdoc fellow, for his important work on improving gene therapy delivery for children with muscular dystrophy. His innovative research—supported by Stollery Kids and Women & Children's Health Research Institute paving the way toward safer and more effective treatments.